A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
ConditionAlzheimer's Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorEisai Korea Inc.
About this trial
The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.
Eligibility criteria
Qualifiers
Enrolled in JOY-ALZ before the decision to treat with LEQEMBI
The clinical decision to treat with LEQEMBI has already been made
Provides written informed consent for the use of medical information to be shared with Eisai Korea Inc.
Disqualifiers
Currently participating in an interventional clinical study
Trial design
Treatments tested in this trial
- No Intervention
Treatment groups
3,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov